(S (PP (IN For) (NP (JJ prostate) (NN cancer) (NNS patients))) (, ,) (NP (DT the) (NNP Gleason) (NN score)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (JJ important)) (JJ prognostic) (NNS factors)))) (, ,) (S (ADVP (RB potentially)) (VP (VBG determining) (NP (NP (NN treatment)) (ADJP (JJ independent) (PP (IN of) (NP (DT the) (NN stage)))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NNP Gleason) (VBG scoring)) (VP (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (JJ subjective) (NN microscopic) (NN examination)) (PP (IN of) (NP (NN tumor) (NN morphology))))))) (CC and) (VP (NNS suffers) (PP (IN from) (NP (JJ poor) (NN reproducibility))))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (JJ deep) (NN learning) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP DLS)) (-RRB- -RRB-)) (PP (IN for) (S (NP (NNP Gleason)) (VP (VBG scoring) (NP (NP (JJ whole-slide) (NNS images)) (PP (IN of) (NP (NNS prostatectomies))))))))) (. .))
(S (NP (PRP$ Our) (NN system)) (VP (VBD was) (VP (VP (VBN developed) (S (VP (VBG using) (NP (NP (QP (CD 112) (CD million)) (JJ pathologist-annotated) (NN image) (NNS patches)) (PP (IN from) (NP (CD 1,226) (NNS slides))))))) (, ,) (CC and) (VP (VBD evaluated) (PP (IN on) (NP (NP (DT an) (JJ independent) (NN validation) (NN dataset)) (PP (IN of) (NP (CD 331) (NNS slides))) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (DT the) (NN reference) (NN standard)) (VP (VBD was) (VP (VBN established) (PP (IN by) (NP (JJ genitourinary) (NN specialist) (NNS pathologists)))))))))))) (. .))
(S (PP (IN On) (NP (DT the) (NN validation) (NN dataset))) (, ,) (NP (NP (DT the) (JJ mean) (NN accuracy)) (PP (IN among) (NP (CD 29) (JJ general) (NNS pathologists)))) (VP (VBD was) (NP (CD 0.61))) (. .))
(S (NP (DT The) (NNP DLS)) (VP (VP (VBD achieved) (NP (NP (DT a) (ADJP (RB significantly) (RBR higher)) (JJ diagnostic) (NN accuracy)) (PP (IN of) (NP (NP (CD 0.70)) (PRN (-LRB- -LRB-) (NP (NN p=0.002)) (-RRB- -RRB-)))))) (CC and) (VP (VBD trended) (PP (NNS towards) (NP (NP (RBR better) (NN patient) (NN risk) (NN stratification)) (PP (IN in) (NP (NP (NNS correlations)) (PP (TO to) (NP (JJ clinical) (JJ follow-up) (NNS data))))))))) (. .))
(S (NP (PRP$ Our) (NN approach)) (VP (MD could) (VP (VB improve) (NP (NP (DT the) (NN accuracy)) (PP (IN of) (NP (NP (NNP Gleason) (VBG scoring)) (CC and) (NP (JJ subsequent) (NN therapy) (NNS decisions))))) (, ,) (SBAR (ADVP (RB particularly)) (WRB where) (S (NP (JJ specialist) (NN expertise)) (VP (VBZ is) (ADJP (JJ unavailable))))))) (. .))
(S (NP (DT The) (NNP DLS)) (ADVP (RB also)) (VP (VBZ goes) (PP (IN beyond) (NP (DT the) (JJ current) (NNP Gleason) (NN system))) (S (VP (TO to) (VP (ADVP (RBR more) (RB finely)) (VB characterize) (CC and) (VB quantitate) (NP (NN tumor) (NN morphology))))) (, ,) (S (VP (VBG providing) (NP (NP (NNS opportunities)) (PP (IN for) (NP (NP (NN refinement)) (PP (IN of) (NP (NP (DT the) (NNP Gleason) (NN system)) (NP (PRP itself)))))))))) (. .))
